Adrenergic Uptake Inhibitors - Therapeutic use
Research News and Information

Monday, November 23, 2009

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]

30 Aug 2009 Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

30 Aug 2009 Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric co-morbidity, and approximately 60% have at ... Read more...

Treatment of hyperkinetic movement disorders.

30 Aug 2009 Parkinson's disease, the most common hypokinetic movement disorder, has received much attention from the clinical and scientific community, but there has been a relative paucity of comprehensive reviews of hyperkinetic disorders, even though they ... Read more...

Latest indexed articles for 'Adrenergic Uptake Inhibitors - Therapeutic use'

These are the very latest articles for this heading:

• Rapid improvement in affective information processing after acute administration of reboxetine. 29 Sep 2009
• [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
• Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. 30 Aug 2009
• Treatment of hyperkinetic movement disorders. 30 Aug 2009
• Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. 30 Aug 2009
• Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression. 14 Jul 2009
• Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 30 Jun 2009
• Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. 29 Jun 2009
• Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. 29 Jun 2009
• Milnacipran (savella) for fibromyalgia. 13 Jun 2009
• [Therapy for urinary incontinence in general practice] 31 May 2009
• New drugs 09, part 2. 30 May 2009
• Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. 30 May 2009
• Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. 30 May 2009
• Attention-deficit-hyperactivity disorder: an update. 30 May 2009
• [Treatment of female urinary incontinence] 26 May 2009
• Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. 24 May 2009
• The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. 29 Apr 2009
• Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting. 29 Apr 2009
• [Therapeutic use of tetrabenazine] 29 Apr 2009

See a longer list of these articles.

Technical information about 'Adrenergic Uptake Inhibitors'

Definition: Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Registry Number: 0

Descriptor UI: D018759

Alternative terms: Adrenergic Uptake Inhibitors; Reuptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Uptake; Uptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Reuptake; Adrenergic Reuptake Inhibitors;

Related Mesh Headings: Amphetamines; Antidepressive Agents, Tricyclic; Dopamine Uptake Inhibitors;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.625.050.601; D27.505.519.625.600.050; D27.505.696.577.050.601; D27.505.696.577.600.050;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics; DF: ADREN UPTAKE INHIB